"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Descriptor ID |
D009101
|
| MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
| Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myelomas, Multiple
- Myeloma, Multiple
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 3 | 0 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 3 | 5 |
| 2006 | 3 | 1 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 4 | 1 | 5 |
| 2009 | 5 | 3 | 8 |
| 2010 | 4 | 3 | 7 |
| 2011 | 10 | 2 | 12 |
| 2012 | 12 | 0 | 12 |
| 2013 | 7 | 0 | 7 |
| 2014 | 11 | 2 | 13 |
| 2015 | 10 | 0 | 10 |
| 2016 | 11 | 0 | 11 |
| 2017 | 16 | 2 | 18 |
| 2018 | 11 | 1 | 12 |
| 2019 | 15 | 0 | 15 |
| 2020 | 23 | 0 | 23 |
| 2021 | 11 | 0 | 11 |
| 2022 | 18 | 0 | 18 |
| 2023 | 15 | 0 | 15 |
| 2024 | 14 | 0 | 14 |
| 2025 | 19 | 0 | 19 |
| 2026 | 12 | 0 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma. JCO Precis Oncol. 2026 Jul; 10(7):e2501121.
-
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026 07 14; 10(13):4541-4550.
-
Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e517460.
-
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med. 2026 May 27; 18(851):eadx1799.
-
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1. J Clin Oncol. 2026 Aug; 44(22):e113-e124.
-
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies. Clin Lymphoma Myeloma Leuk. 2026 Jul; 26(7):423-435.e3.
-
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer Immunol Res. 2026 Apr 02; 14(4):528-542.
-
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol. 2026 Apr; 13(4):e241-e253.
-
Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement. J Natl Compr Canc Netw. 2026 Mar 09; 24(5).
-
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers. Curr Med Res Opin. 2026 01; 42(1):169-178.